Ann Oncol: The efficacy of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed anti-PD-1

Regulation of DNA damage response and repair (DDR) pathways is a promising strategy for tumor immunotherapy
.

Ceralasertib (AZD6738) is an oral inhibitor of serine/threonine protein kinase and Rad3-related protein, which is essential for DDR

Regulation of DNA damage response and repair (DDR) pathways is a promising strategy for tumor immunotherapy

Of the 30 patients included in the study, 29 were assessed for response, with a median follow-up of 14.
5 months
.

Nine patients (30.

Of the 30 patients included in the study, 29 were assessed for response, with a median follow-up of 14.

Median progression-free survival (PFS) was 7.
1 months (95% CI, 3.
6-10.
6 months) and median OS was 14.
2 months (95% CI, 9.
3-19.
1 months)
.

Exploratory analyses revealed no significant differences in survival among subgroups stratified by clinicopathological features

Median progression-free survival (PFS) was 7.

Treatment-emergent adverse events (AEs) of different grades occurred in 29 (96.
7%) patients
.

More than half of the patients had anemia (76.

Treatment-emergent adverse events (AEs) of different grades occurred in 29 (96.

Exploratory biomarker analysis showed that tumors with immune-enhancing microenvironments or altered DDR pathways were more likely to respond to the study treatment
.

Exploratory biomarker analysis showed that tumors with immune-enhancing microenvironments or altered DDR pathways were more likely to respond to the study treatment
.

Exploratory biomarker analysis showed that tumors with immune-enhancing microenvironments or altered DDR pathways were more likely to respond to the study treatment

Taken together, the study shows that ceralasertib (AZD6738) combined with the PD-L1 inhibitor durvalumab is a promising treatment option
.

Taken together, the study shows that ceralasertib (AZD6738) combined with the PD-L1 inhibitor durvalumab is a promising treatment option
.

Studies have shown that ceralasertib (AZD6738) in combination with the PD-L1 inhibitor durvalumab is a promising treatment option

Original source:

Kim R, Kwon M, An M, Kim ST, Smith SA, Loembé AB, Mortimer PGS, Armenia J, Lukashchuk N, Shah N, Dean E, Park WY, Lee J.
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy.
Ann Oncol.
2022 Feb;33(2):193-203.
doi: 10.
1016/j.
annonc.
2021.
10.
009.
Epub 2021 Oct 25 .
PMID: 34710570.

Kim R, Kwon M, An M, Kim ST, Smith SA, Loembé AB, Mortimer PGS, Armenia J, Lukashchuk N, Shah N, Dean E, Park WY, Lee J.
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy.
Ann Oncol.
2022 Feb;33(2):193-203.
doi: 10.
1016/j.
annonc.
2021.
10.
009.
Epub 2021 Oct 25 .
PMID: 34710570.
Leave a message here